N
54.26
-1.76 (-3.14%)
| Previous Close | 56.02 |
| Open | 55.97 |
| Volume | 685,029 |
| Avg. Volume (3M) | 1,013,581 |
| Market Cap | 1,031,947,712 |
| Price / Sales | 11.32 |
| Price / Book | 2.91 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -152.49% |
| Operating Margin (TTM) | -424.15% |
| Diluted EPS (TTM) | -9.45 |
| Quarterly Revenue Growth (YOY) | -51.70% |
| Total Debt/Equity (MRQ) | 1,358.71% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | -176.87 M |
| Levered Free Cash Flow (TTM) | -47.84 M |
| Return on Assets (TTM) | -26.80% |
| Return on Equity (TTM) | -189.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Nektar Therapeutics | Bullish | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.13 |
|
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.29% |
| % Held by Institutions | 67.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Emerald Mutual Fund Advisers Trust | 30 Sep 2025 | 233,205 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 105.00 (B. Riley Securities, 93.51%) | Buy |
| Median | 102.50 (88.91%) | |
| Low | 100.00 (BTIG, 84.30%) | Buy |
| Average | 102.50 (88.91%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 57.37 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 23 Sep 2025 | 105.00 (93.51%) | Buy | 59.60 |
| BTIG | 19 Sep 2025 | 100.00 (84.30%) | Buy | 55.14 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Oct 2025 | Announcement | Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London |
| 28 Oct 2025 | Announcement | Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets |
| 22 Oct 2025 | Announcement | Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting |
| 18 Sep 2025 | Announcement | Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 |
| 09 Sep 2025 | Announcement | Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 |
| 03 Sep 2025 | Announcement | Nektar Therapeutics to Participate in Two Investor Conferences in September |
| 07 Aug 2025 | Announcement | Nektar Therapeutics Reports Second Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |